



OPEN ACCESS

Edited by:

Francisco Ciruela,
University of Barcelona, Spain

Reviewed by:

Tycho Hoogland,
Erasmus University Rotterdam,
Netherlands

Chuang Wang,
Ningbo University, China

***Correspondence:**

Esmerilda G. Delicado
esmerild@ucm.es

† Present address:

Silvia González-Ramos,
Instituto de Investigaciones
Biomédicas Alberto Sols,
Centro Mixto del Consejo Superior
de Investigaciones Científicas,
Universidad Autónoma de Madrid,
Madrid, Spain
Lisardo Boscá,
Instituto de Investigaciones
Biomédicas Alberto Sols,
Centro Mixto del Consejo Superior
de Investigaciones Científicas,
Universidad Autónoma de Madrid,
Madrid, Spain;
Departamento de Bioquímica y
Biología Molecular IV, Facultad
de Veterinaria, Universidad
Complutense Madrid, Madrid, Spain

Specialty section:

This article was submitted to
Experimental Pharmacology and
Drug Discovery,
a section of the journal
Frontiers in Pharmacology

Received: 16 October 2017

Accepted: 11 December 2017

Published: 22 December 2017

Citation:

Paniagua-Herranz L,
Gil-Redondo JC, Queipo MJ,
González-Ramos S, Boscá L,
Pérez-Sen R, Miras-Portugal MT and
Delicado EG (2017) Prostaglandin E₂
Impairs P2Y₂/P2Y₄ Receptor
Signaling in Cerebellar Astrocytes via
EP3 Receptors.
Front. Pharmacol. 8:937.
doi: 10.3389/fphar.2017.00937

Prostaglandin E₂ Impairs P2Y₂/P2Y₄ Receptor Signaling in Cerebellar Astrocytes via EP3 Receptors

Lucía Paniagua-Herranz, Juan C. Gil-Redondo, M^a José Queipo, Silvia González-Ramos[†], Lisardo Boscá[†], Raquel Pérez-Sen, M^a Teresa Miras-Portugal and Esmerilda G. Delicado*

Departamento de Bioquímica y Biología Molecular IV, Facultad de Veterinaria, Instituto Universitario de Investigación en Neuroquímica, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Universidad Complutense Madrid, Madrid, Spain

Prostaglandin E₂ (PGE₂) is an important bioactive lipid that accumulates after tissue damage or inflammation due to the rapid expression of cyclooxygenase 2. PGE₂ activates specific G-protein coupled EP receptors and it mediates pro- or anti-inflammatory actions depending on the cell-context. Nucleotides can also be released in these situations and they even contribute to PGE₂ production. We previously described the selective impairment of P2Y nucleotide signaling by PGE₂ in macrophages and fibroblasts, an effect independent of prostaglandin receptors but that involved protein kinase C (PKC) and protein kinase D (PKD) activation. Considering that macrophages and fibroblasts influence inflammatory responses and tissue remodeling, a similar mechanism involving P2Y signaling could occur in astrocytes in response to neuroinflammation and brain repair. We analyzed here the modulation of cellular responses involving P2Y₂/P2Y₄ receptors by PGE₂ in rat cerebellar astrocytes. We demonstrate that PGE₂ inhibits intracellular calcium responses elicited by UTP in individual cells and that inhibiting this P2Y signaling impairs the astrocyte migration elicited by this nucleotide. Activation of EP3 receptors by PGE₂ not only impairs the calcium responses but also, the extracellular regulated kinases (ERK) and Akt phosphorylation induced by UTP. However, PGE₂ requires epidermal growth factor receptor (EGFR) transactivation in order to dampen P2Y signaling. In addition, these effects of PGE₂ also occur in a pro-inflammatory context, as evident in astrocytes stimulated with bacterial lipopolysaccharide (LPS). While we continue to investigate the intracellular mechanisms responsible for the inhibition of UTP responses, the involvement of novel PKC and PKD in cerebellar astrocytes cannot be excluded, kinases that could promote the internalization of P2Y receptors in fibroblasts.

Keywords: astrocytes, calcium, EP receptors, nucleotide receptor, P2Y receptors, PGE₂

Abbreviations: [Ca²⁺]_i, intracellular free calcium concentration; DMEM, Dulbecco's modified Eagle's medium; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal regulated kinases; FCS, fetal calf serum; GPCRs, G protein-coupled receptors; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LPS, lipopolysaccharide; MEK, mitogen extracellular activated kinases; NGF, nerve growth factor; PI-3 kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase; nPKC, novel protein kinase C; PKD, protein kinase D; PPADS, pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; PGs, prostaglandins; PGE₂, prostaglandin E₂.

INTRODUCTION

Prostaglandins are bioactive lipids produced through the metabolism of arachidonic acid by cyclooxygenase and they play important modulatory roles throughout the body (Sugimoto and Narumiya, 2007). Both COX-1 and COX-2 display cyclooxygenase activity, which are constitutive and inducible enzymes, respectively (Smith et al., 2000). These enzymes convert the arachidonic acid released following phospholipase A₂ (PLA₂) activation from membrane lipids into PGH₂, the precursor of both PGs and thromboxanes. One of the principal activators of PLA₂ is intracellular calcium, which brings arachidonic acid production under the control of multiple extracellular signals, including extracellular nucleotides (Zonta et al., 2003). PGE₂ is one of the most studied PGs, and not only is it the most widely found in different animal species (including humans) but it also exhibits the most versatile actions. Through specific membrane receptors, PGE₂ fulfills many physiological functions, such as gastrointestinal mucosa protection or labor, as well as participating in pathological events like inflammation or fever. Indeed, the cyclooxygenase enzymes have been widely explored in anti-inflammatory therapies, although the majority of COX inhibitors display side effects due to COX-1 inhibition, mainly gastrointestinal bleeding and renal toxicity (Dannhardt and Kiefer, 2001; Dwivedi et al., 2015).

Prostaglandin E₂ activates specific GPCRs, named EP receptors. Four different EP receptor subtypes have been identified, EP1–EP4, which differ in the signal transduction pathways they use, their distribution and the regulation of their expression (St-Jacques and Ma, 2016). The EP1 receptor is mainly coupled to Gq proteins and its stimulation induces intracellular calcium responses. By contrast, the EP2 and EP4 receptors are coupled to Gs proteins and they produce an accumulation of cAMP, whereas the EP3 receptor is mainly coupled to Gi proteins and it provokes a decrease in the cAMP produced in response to Gs-protein coupled receptor stimulation. There are three EP3 splice variants (α , β , and γ), each of which contains a distinct C-terminal tail of 30, 26, and 29 amino acids, respectively. These isoforms all have similar ligand binding properties but they activate different signal transduction pathways. Indeed, the EP3 variants not only couple to Gi proteins but also, to Gq proteins, Rho or even adenylate cyclase. In addition, some effects of PGE₂ are exerted independently of EP receptors and other intracellular targets have even been proposed (Traves et al., 2013).

Extracellular nucleotides are also important extracellular messengers (Burnstock, 2006; Miras-Portugal et al., 2016). Nucleotides can be released from living cells under basal conditions and their release is enhanced by cell stressors, including mechanical stress, hypoxia, viral infection or pro-apoptotic stimuli. Nucleotides are stored in secretory vesicles along with biogenic amines and other neurotransmitters, and they are released by exocytosis (Lazarowski et al., 2011). Once in the extracellular space, nucleotides interact with specific membrane nucleotide receptors, which are classified in two main types: the ionotropic P2X receptors and the metabotropic P2Y receptors. Seven P2X nucleotide receptors have been identified and they are trimeric ATP-activated ion channels

that are permeable to Na⁺, K⁺, and Ca²⁺ (North, 2016). Metabotropic P2Y receptors belong to the superfamily of GPCRs and unlike P2X receptors, they can be activated by adenine and/or uridine nucleotides (ATP, ADP, UTP, and UDP) and nucleotide sugars (UDP-glucose). Eight subtypes of P2Y receptors have been identified that have been classified in two main subfamilies according to their pharmacology, signal transduction and structure (Costanzi et al., 2004; von Kugelgen and Hoffmann, 2016). The first of these is coupled to Gq proteins and phospholipase C (PLC), and it includes the P2Y₁, P2Y₂, P2Y₄, P2Y₆, and P2Y₁₁ receptors. By contrast, the second one is linked to Gi/Go proteins and it includes the P2Y₁₂, P2Y₁₃, and P2Y₁₄ receptors. However, like other GPCRs, P2Y receptors are promiscuous and additional G protein linkages have been described (Erb and Weisman, 2012). P2X and P2Y receptors are co-expressed throughout the body, and they play important roles in the vascular system, in immune defense and in the nervous system. The extracellular concentration of nucleotides is controlled by a family of ectoenzymes that catalyze the hydrolysis of nucleotides, generating their corresponding diphosphate nucleotides and ultimately, nucleosides. These nucleosides are then taken back up by the cells via nucleoside transporters.

Both, PGE₂ and nucleotides have beneficial or detrimental effects depending on the cell context, and the duration of PGE₂ production or nucleotide release. Furthermore, they can co-exist in the extracellular milieu under physiological and pathological conditions. As mentioned previously, nucleotides can influence PGE₂ production and *vice versa*, PGE₂ may regulate nucleotide activity (Chen and Lin, 2000; Zonta et al., 2003; Ito and Matsuoka, 2008, 2015). In this regard, we previously showed that PGE₂ inhibited P2Y responses in macrophages, particularly those mediated by P2Y receptors sensitive to purine and pyrimidine nucleotides, the metabotropic P2Y₂, P2Y₄, and P2Y₆ receptors. The selective impairment of P2Y signaling by PGE₂ appears to be independent of EP receptors, involving the activation of nPKC and PKD, and with functional implications for the biological responses of macrophages due to the influence on their metabolism and migration. Such interactions take place in thioglycollate-elicited and alternative macrophages, which could contribute to the resolution phase of inflammation (Traves et al., 2013). The same cross-talk between PGE₂ and P2Y signaling has been described in murine fibroblasts, suggesting that macrophages and fibroblasts contribute to the regulation of inflammatory responses and tissue damage repair through aligned mechanisms associated with P2Y signaling. Such cross-talk may open new avenues to develop future anti-inflammatory therapies (Pimentel-Santillana et al., 2014).

In an attempt to investigate whether PGE₂ would modulate nucleotide P2Y responses in the nervous system we decided to analyze this interaction in astrocytes. Thanks to their strategic location in close proximity with neurons and endothelial cells, astrocytes regulate cerebral blood flow to metabolic demands, PGE₂ being one of the first described mediators of cerebral vasodilation (Ellis et al., 1979; Takano et al., 2006). Astrocytes are also able to detect danger signals, secrete cytokines, and activate adaptive defense [see excellent reviews (Sofroniew, 2015; Colombo and Farina, 2016)]. Moreover, the typical hallmark

of brain injury is the upregulation of the astrocyte marker, the glial fibrillary acidic protein (GFAP), as consequence of astrocyte proliferation and the glial scar formation. The impact of astrocytes activity on tissue homeostasis is ambivalent, it may exacerbate inflammatory responses and tissue damage, or promote immunosuppression and tissue repair, depending on timing and context. *In vivo* studies performed in disease models of brain or spinal cord injury and experimental autoimmune encephalomyelitis (EAE) have revealed that the loss of reactive astrocytes during the early phases of injury results in exacerbation of clinical signs, motor deficits, scar disorganization, demyelination and neuronal death. By contrast, astrocyte depletion during chronic phase of EAE ameliorates disease and reduces leukocyte infiltration into nervous system. Recently, it has been described that astrocytes also respond to proinflammatory stimuli with the intense production of PGE₂, adapting cerebral blood flow to neuro-inflammatory demands (Font-Nieves et al., 2012; Howarth et al., 2017).

Astrocytes represent a heterogeneous cell population in terms of their ability to respond to neuroligands linked to calcium mobilization and they are also able to selectively discriminate between the activities of different pathways that use the same neurotransmitter. However, native and cultured astrocytes from different brain areas, cortical, hippocampal and cerebellar astrocytes are sensitive to nucleotides given that they co-express P2Y and P2X nucleotide receptors (Neary et al., 2004; Domercq et al., 2006; Fujita et al., 2009; Peterson et al., 2010; Oliveira et al., 2011). The present study was performed on cultured cerebellar astrocytes, because they constitute a homogeneous cell population that exhibited functional P2Y nucleotide receptors, especially those we are interested, the P2Y₂ and P2Y₄ receptors sensitive to adenine and pyrimidine nucleotide (ATP/UTP). In previous studies we demonstrated that metabotropic ATP calcium responses were submitted to a fine regulation by growth factors (EGF/NGF) and signals coupled to G_s stimulation, such as noradrenaline and adenosine, which would suggest the importance to maintain purinergic tone. Using different approaches we found that PGE₂ inhibits P2Y₂/P2Y₄ signaling in rat cerebellar astrocytes. Indeed, PGE₂ reduced UTP calcium responses and intracellular signaling cascades activated by this nucleotide, as well as preventing UTP-induced cell migration. In astrocytes, the PGE₂ effect appeared to be mediated by EP3 receptors and was also observed in LPS-treated cells.

MATERIALS AND METHODS

Chemicals, Materials, and Antibodies

Papain was purchased from Worthington (Lake Wood, NJ, United States), FCS from Invitrogen and Fura-2 from Molecular Probes (Life Technologies, Barcelona, Spain). Culture flasks, Plastic Petri dishes and transwell chambers with 8 μm pore transparent PET membrane inserts were supplied by Falcon Becton Dickinson Labware (Franklin Lakes, NJ, United States). Antibiotics, DMEM, UTP, and AG1478 were purchased from Sigma Aldrich (St. Louis, MO, United States). PGE₂, and the EP agonists and antagonists, were from Cayman Chemical

(Ann Arbor, MI, United States), while LY294002 was from Calbiochem Co. (San Diego, CA, United States). Specific antibodies against phospho-ERK1/2 (Tyr²⁰⁴), ERK2, phospho-Akt (Thr³⁰⁸) and Akt were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States), and anti-COX-2 was from Abcam (Cambridge, United Kingdom). Antibodies against P2Y receptors, P2Y₂ and P2Y₄ receptors, and those against the EP3 receptor were from Alomone Labs (Jerusalem BioPark, Israel), while antibodies against GAPDH were purchased from Cell Signaling Technology (Beverly, MA, United States). Secondary horseradish peroxidase-conjugated anti-mouse and anti-rabbit antibodies (Dako, Denmark) were used here. All other reagents not specified were routinely supplied by Sigma, Merck (Darmstadt, Germany) or Roche Diagnostics SL (Barcelona, Spain).

Experimental Animals

All the experiments were carried out at the Complutense University of Madrid (Madrid, Spain) following the International Council for Laboratory Animal Science guidelines (ICLAS). All the procedures were approved by both the Animal Ethics Committee of the Complutense University and the Regional Authorities in Madrid (Area of Animal Protection), according to the Spanish Royal Decree RD53/2013 and the European Directive 2010/63/UE on the protection of animals used for scientific purposes. The assays were designed to minimize the number of animals used while maintaining statistical validity.

Astrocyte Cultures

Primary cultures of astrocytes were prepared as described previously with some modifications (Jimenez et al., 1999). Briefly, the cerebellum from Wistar rat pups (P7) was removed aseptically, digested with papain and cerebellar cells were resuspended in DMEM containing 10% FCS (v/v), 25 mM glucose, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2.5 μg/ml amphotericin. The cells were plated in culture flasks at density of 70,000 cells/cm² and they were maintained in culture until reaching confluence (approximately 10–12 days), replacing the medium every 3–4 days. Cultures were depleted of microglial cells by orbital shaking and finally, the astrocytes were detached from the culture flasks by trypsin treatment and seeded onto culture plates. For microfluorometry experiments, astrocytes were plated onto glass coverslips in 35 mm Petri dishes at 50,000 cells/cm² and for Western blotting, cells were plated onto Petri dishes at a density of 35,000 cells/cm². Astrocytes were routinely used 48 h after plating.

Fura-2 Microfluorimetry and Calcium Imaging

Calcium imaging experiments were carried out essentially as described previously (Carrasquero et al., 2005). Astrocytes attached to coverslips were incubated in Locke's solution (composition in mM: 140 NaCl, 4.5 KCl, 2.5 CaCl₂, 1.2 KH₂PO₄, 1.2 MgSO₄, 5.5 glucose, 10 HEPES pH 7.4) supplemented with 1 mg/mL bovine serum albumin (BSA) and loaded with 5–7 μM fura-2/AM for 45 min at 37°C. Once washed in fresh

Locke's solution, a coverslip was placed in a small superfusion chamber and the cells were imaged on a NIKON TE-200 microscope equipped with a Plan Fluor 20X/0.5 objective. Cells were continuously superfused with Locke's medium at a rate of 1.5 mL/min, and agonists were usually applied for 20 s by switching the superfusion solution with the aid of WC-8 valve controller (Warner Instruments). Cells were illuminated at 340 and 380 nm, and the emitted light was isolated with a dichroic mirror (430 nm) and a 510 nm band-pass filter (Omega Optical). Images were obtained with an ORCA-ER C 47 42-80 camera (Hamamatsu City, Japan) controlled by MetaFluor 6.2r and PC software (Universal Imaging, Corp., Cambridge, United Kingdom). The exposure time was 100 ms and the wavelength of incoming light was changed from 340 to 380 nm in less than 5 ms. Fluorescence images were acquired at a sampling frequency of 2 Hz and processed by averaging signals from small elliptical regions within individual cells. Background signals were subtracted from each wavelength and the F₃₄₀/F₃₈₀ fluorescence ratio was calculated. Fluorescence ratio increases represent [Ca²⁺]_i changes. The quantification of the responses was made by measuring the magnitude of the initial transients. Data are represented as the percentage of the control responses elicited by an UTP challenge in the same experimental conditions (each individual cell).

Migration Assays

Astrocytes were detached from the culture flasks and they were suspended in DMEM supplemented with 1% FCS. The lower chambers of Transwell 6-well culture plates were filled with 3 mL DMEM containing UTP (as indicated), and with an 8 μm membrane insert placed into the wells, a 1 mL cell suspension containing 300,000 cells was added to the upper chamber. After 18 h at 37°C in a 5% CO₂ incubator, the cells in the upper chambers were removed by scraping the membranes with a cotton swab, while the cells attached to the bottom of the membranes were fixed with 4% paraformaldehyde for 15 min, washed with PBS and stained with the nuclear marker, DAPI. The cells were visualized under a microscope and counted in five random fields. They cells attached to the bottom of the membrane represented those that had migrated from the upper to lower chamber in response to nucleotide stimulation.

In Vitro Wound Healing

Astrocytes detached from culture flasks were seeded onto Petri dishes in complete culture medium and they were maintained in the incubator to form a confluent monolayer (48 h after plating). A wound was made by scraping a conventional yellow pipette tip across the monolayer and the cells were then washed with culture medium, replacing the medium with fresh DMEM plus 1% FCS and with the addition of the nucleotide or another effector to induce migration. After 24 h at 37°C in a 5% CO₂ incubator, the cells were fixed with paraformaldehyde as described above and their nucleus was stained with DAPI.

Cell Treatments and Lysate Preparations

Cells were stimulated in Locke's solution and where indicated, the astrocytes were preincubated in the presence or absence

of effectors, antagonists or inhibitors prior to stimulation with the nucleotide UTP. Controls were systematically used with the corresponding vehicle alone (DMSO always at a concentration <2%), in which cell viability was not significantly affected. Incubations were stopped by removing the incubation medium and lysing the cells in cold lysis buffer (20 mM MOPS pH 7.2, 50 mM NaF, 40 mM β-glycerophosphate, 1 mM sodium orthovanadate, 5 mM EDTA, 2 mM EGTA, 0.5% Triton X-100, 1 mM PMSF, and a protease inhibitor cocktail).

Western Blotting

Total cellular lysates (15–30 μg protein) were resolved in SDS-PAGE gels and transferred to PVDF membranes. The membranes were probed overnight at 4°C with primary antibodies in either TBS 0.1% with Tween-20 containing low-fat milk powder (5%, w/v), and then for 1 h at room temperature with the secondary antibodies. Antibodies were used at following dilutions: anti-phosphor-ERK1/2, anti-ERK2 (1:1000), anti-phosphor Akt and Akt (1:1000), anti-COX-2 (1:500), anti-P2Y₂ and anti-P2Y₄ (1:200), anti-EP3 receptors (1:200), and anti-mouse and anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:2000 and 1:1000, respectively). Specific protein bands were visualized by ECL (Western Lighting ECL PRO kit, Perkin Elmer, Madrid, Spain), and chemiluminescence images were taken with the ImageQuant LAS 500[®] image system and quantified by densitometry using ImageQuantTL software.

Statistical Analysis

The results are expressed as the means ± SEM calculated from at least three experiments performed on cells from different cultures. When multiple comparisons were made, one-way analysis of variance was used and Dunnett's post-test analysis was applied only when a significant ($p < 0.05$) effect was indicated by the one-way analysis of variance (GraphPad Prism 5; GraphPad Software, Inc., San Diego, CA, United States).

RESULTS

PGE₂ Modulates Metabotropic ATP Calcium Responses in Individual Cerebellar Astrocytes

Cerebellar astrocytes co-express several subtypes of P2Y metabotropic nucleotide receptors (Jimenez et al., 2000), and metabotropic calcium responses to ATP mediated by P2Y₂/P2Y₄ nucleotide receptors were evident in the entire astrocyte population, in which ATP and UTP were equipotent. To examine the modulatory role of PGE₂ on P2Y signaling in cerebellar astrocytes, we investigated the effect of this prostaglandin on UTP induced calcium responses. We did not use ATP, because cerebellar astrocytes also express ATP sensitive P2X₇ receptors (Carrasquero et al., 2009). As expected all the cells tested responded to the UTP challenge (100 μM) by increasing their intracellular calcium [Ca²⁺]_i, which peaked ($\Delta F_{340}/F_{380}$ of 0.73 ± 0.02 relative to the basal levels between

0.3 and 0.5; $n = 327$ cells) and then returned to the basal level within the first 20 s of stimulation (**Figure 1A**). These cells also responded to a second UTP challenge with similar calcium transients, the magnitude of which was reduced by 10%. It is known that EP1 receptors couple to G_q proteins and EP2 receptor stimulation promotes calcium responses in rat cortical astrocytes (Di Cesare et al., 2006). Thus, before analyzing the modulatory role of PGE₂ on UTP calcium responses, cells were challenged with PGE₂ (1 μ M) alone, which did not evoke any increase in $[Ca^{2+}]_i$. Cells were also insensitive to stimulation with 6,16-Dimethylprostaglandin E₂, a synthetic analog that resists metabolism and that has a prolonged half-life *in vivo* (results not shown). These results indicated that cerebellar astrocytes did not express functional EP1 receptors, although they did not rule out the presence of functional EP2/EP4 receptors coupled to adenylate cyclase activation. PGE₂ inhibited UTP calcium responses (**Figure 1B**) and preincubation with PGE₂ (1 μ M, 5 min) dampened the calcium responses elicited by 100 μ M UTP, the maximal effective concentration. This inhibition was observed in all the cells tested and the magnitude of the initial Ca²⁺ transient was reduced by a 40%. Nevertheless, the effect of preincubation with PGE₂ was not necessary due to the simultaneous co-stimulation of astrocytes with PGE₂ and UTP reduced the calcium responses triggered by the nucleotide alone by 35%. These results were consistent with the regulatory influence of PGE₂ on P2Y signaling evident in macrophages and fibroblasts (Ito and Matsuoka, 2008; Traves et al., 2013; Pimentel-Santillana et al., 2014).

The presence of EP2/EP4 receptors coupled to G_s proteins in cerebellar astrocytes was analyzed indirectly, assessing whether UTP-mediated responses could be enhanced by PGE₂ (**Figure 2**). We previously reported an important cross-talk between G_s-coupled receptors and P2Y nucleotide receptors in these glial cells (Jimenez et al., 1999). Indeed, the activation of A_{2B} adenosine receptors, or other signals coupled to adenylate cyclase stimulation, strongly potentiated the metabotropic calcium responses to nucleotides. Co-stimulation of astrocytes with adenosine (10 μ M) and ATP (1 μ M, ineffective when administered alone) elicited $[Ca^{2+}]_i$ transients that represented 60% of the maximal calcium response elicited by ATP/UTP (100 μ M). This potentiation was parallel to but independent of cAMP accumulation, suggesting the involvement of $\beta\gamma$ subunits released upon G_s stimulation. Co-stimulation of astrocytes with PGE₂ and ineffective concentrations of UTP (1 μ M) did not evoke any signals (**Figure 2**), and no signal was observed after preincubation with PGE₂ and simultaneous co-stimulation with UTP (1 μ M). Hence, cerebellar astrocytes do not appear to express functional EP2/EP4 receptors and if they are present, they were unable to modulate UTP calcium responses in the same way as other signals coupled to adenylate cyclase activation.

Having excluded the participation of EP1 and EP2/EP4 receptors in the inhibitory effect of PGE₂ on the calcium responses to UTP, we assessed the involvement of EP3 receptors in this effect (**Figure 3**). The EP3 agonist sulprostone is a synthetic analog of PGE₂ that is resistant to metabolism and



it reproduced the effect of PGE₂ (**Figure 4A**). Stimulation with UTP (100 μ M) after preincubation with sulprostone (30 nM, 5 min) dampened the calcium responses, which reached 57.44% of the control responses. Likewise, co-stimulation with sulprostone and UTP resulted in calcium responses that reached 61.71% of the control UTP responses. These findings supported the involvement of EP3 receptors in this phenomenon. In fact, EP3 receptors were detected in Western blots, although assays carried out with an EP3 receptor antagonist, L798106 ((2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide), proved inconclusive. This antagonist did not modify the basal calcium levels but it did depress the calcium responses to UTP by 40% (**Figure 4B**). Moreover, pretreatment of astrocytes with L798106 prior to their stimulation with PGE₂ or sulprostone did not prevent their inhibitory effects. Thus, despite the detection of EP3 receptors in Western blots (**Figure 8**), their involvement in the regulatory effect of PGE₂ remained unclear. Indeed, we suggest that L798106 might be interacting with P2Y receptors given its similar structure to non-selective antagonists of nucleotide receptors, such as PPADS or suramin (Ho et al., 1995; Communi et al., 1996; Jimenez et al., 2000).

PGE₂ Impairs the Cell Migration Induced by UTP in Cerebellar Astrocytes

We next examined whether PGE₂ modulated the migration of cerebellar astrocytes induced by UTP, as reported in macrophages and fibroblasts (Pimentel-Santillana et al., 2014). In both assays used, transwell migration and wound-healing, PGE₂ attenuated the migration of astrocytes induced by UTP (**Figure 5**). When UTP (100 μ M) was added to the lower transwell chamber of cell culture dishes containing membrane inserts, transmembrane chemotactic migration of astrocytes was enhanced (**Figure 5A**). However, preincubation of cells with PGE₂ (1 μ M, 5 min) prior to their introduction into the upper chamber diminished their migration under control conditions and that induced by the nucleotide by 45%. UTP-induced chemotaxis was also prevented by U0126 (**Figure 5A**), an inhibitor of MEK, which indicated that ERK activation was required for cell migration. In wound-healing migration assays, PGE₂ completely prevented cell migration in control conditions (without additional exogenous nucleotide), as well as that induced by the nucleotide (**Figure 5B**). In this case, prostaglandin was included in the fresh medium added after the cells were washed to remove cell debris.


Characterization of the Intracellular Mechanism Used by PGE₂ to Modulate the Responses to UTP

The impact of PGE₂ on the intracellular signaling cascades triggered by UTP was analyzed to further study the mechanism through which PGE₂ modulates UTP responses. The ERK1/2 and PI3-kinase/Akt proteins are known to play relevant roles in nucleotide signaling and cell migration (Brambilla et al., 2002; Jimenez et al., 2002; Neary et al., 2004). Indeed, stimulation



of astrocytes with UTP (100 μM) induced a remarkable increase in the phosphorylation of ERK1/2 (a fourfold to eightfold increase over basal levels) and of the Akt protein (a twofold increase over basal levels: **Figure 6**). Pretreatment of astrocytes with PGE₂ (1 μM) reduced the ERK and Akt phosphorylation induced by UTP 35 and 40%, respectively. Stimulating astrocytes with PGE₂ alone had no significant effect

on ERK phosphorylation but it did dampen the phosphorylation of Akt. The inhibitory effects of PGE₂ were also reproduced by sulprostone. Preincubation with the prostanoids was not necessary, and similar effects were observed after co-stimulation with PGE₂/sulprostone and the nucleotide (results not shown). The extent of inhibition is consistent with the changes in the calcium responses observed.




EGFR Is Required for PGE₂ to Modulate UTP-Induced ERK1/2 and PI3-K/Akt Activation

The EGF receptor plays a key role in the intracellular signaling cascades triggered by GPCRs, including P2Y₂ receptors (Liu et al., 2004). To determine whether EGFR activation was required for the activation of ERK and/or Akt by the nucleotide, or for the modulatory effect of PGE₂, the influence of an EGFR tyrosine kinase inhibitor was tested, AG1478. Interestingly, pretreatment of cells with AG1478 (1 μM) for 20 min reduced the basal phosphorylation of the two kinases, although it did not affect the UTP-induced ERK and Akt phosphorylation (Figure 7). Nevertheless, the EGFR inhibitor impaired the regulatory effect of PGE₂, indicating that EGFR transactivation was required for the effect of the prostaglandin. Moreover, inhibition of PI3K with LY294002 (50 μM, 20 min) not only reduced the basal phosphorylation of ERK but it also prevented the regulatory effect of PGE₂, although like the EGFR inhibitor it did not affect UTP-induced ERK phosphorylation. Thus, PGE₂ could regulate ERK and Akt activation by a mechanism dependent on the transactivation of the EGFR and PI3K kinase, which would also support the involvement of EP3 receptors. To clearly demonstrate the possible implication of these receptors, more comprehensive studies will be necessary

that take into account the different splice variants of these receptors described.

Modulation of UTP-Induced ERK1/2 and PI3-K/Akt Activation by PGE₂ in Astrocytes Activated with LPS

To determine whether the modulation of PGE₂ might be relevant to neuroinflammation and pathological conditions, we investigated the cross-talk between PGE₂ and nucleotides in astrocytes treated with LPS, a toll-like receptor (TLR) ligand. Pretreatment with LPS (10 ng/mL, 24 h) did not affect either UTP-induced ERK phosphorylation or the modulatory effect of PGE₂ (Figure 8A). UTP-induced ERK activation was higher (a 7.98-fold increase over unstimulated cells) than that observed in untreated cells (4.5-fold increase over basal levels) in the same experimental conditions, while PGE₂ decreased UTP-induced ERK activation by 55%. Pretreatment of astrocytes with LPS notably increased the basal levels of the Akt phosphorylation and it diminished UTP-induced Akt phosphorylation by 55% (Figure 8B). In addition, PGE₂ prevented Akt activation induced by the nucleotide. LPS induced strong expression of COX-2 (twofold over basal) but it did not significantly modify the levels of P2Y₂/P2Y₄ receptors in cerebellar astrocytes. Note that as reported previously, the P2Y₂ receptor is more abundant in these



cells than the P2Y₄ receptor. Nevertheless, LPS also increased the levels of EP3 receptors (twofold to threefold increase over basal levels) (**Figure 8C**).

DISCUSSION

The current study was carried out on cultured rat cerebellar astrocytes, a good model to address the regulation of nucleotide P2Y receptors. We previously characterized the function of the different P2Y receptors present in individual astrocytes by microfluorimetry using fura-2 (Jimenez et al., 2000). We found that all astrocytes in our cultures were sensitive to ATP/UTP stimulation, which provoked a metabotropic calcium response. Furthermore, the metabotropic ATP calcium responses mediated by P2Y₂/P2Y₄ receptors were modulated by other agonists of the purinergic system, such as adenosine, the final product of extracellular nucleotide degradation, and the dinucleotide Ap₅A, which is also stored in secretory vesicles and that has potentiating activity (Jimenez et al., 1999, 2002; Delicado et al., 2005). Similar effects were observed with signals that activated G_s-coupled receptors and with EGF. Here we identified

another mechanism that regulates the metabotropic calcium responses to ATP and we demonstrate that PGE₂ inhibits UTP signaling in cerebellar astrocytes, not only impairing intracellular calcium mobilization but also dampening ERK activation, activation of the PI3K/Akt axis, and impairing cell migration (**Figure 9**).

The effect of PGE₂ on UTP driven calcium responses was also evaluated at the single cell level. The fact that PGE₂ modulation was observed in all the cells tested suggests universal and homogenous expression of the P2Y₂/P2Y₄ receptors of UTP in these glial cells, although it also indicated that a specific target for PGE₂ might be present in these cells. In fact, although, most of the studies were performed on cell populations, the 40% inhibition displayed by PGE₂ was similar to that obtained in individual cells. Although glial cells had more P2Y₂ and P2Y₄ receptors than murine macrophages, the inhibitory effect of PGE₂ on UTP calcium responses in astrocytes was weaker than that found in macrophages and fibroblasts, in which it accounted for 60–70% inhibition (Traves et al., 2013). Nevertheless, the data gathered here indicate astrocytes are another cell type involved in tissue remodeling, in which PGE₂ negatively modulates UTP and/or ATP responses, in addition to macrophages and fibroblasts.





FIGURE 5 | Prostaglandin E₂ impairs rat cerebellar astrocyte migration. **(A)** The capacity of astrocytes to migrate in the Transwell assay. Cells were added to the upper chamber of transwell plates with inserts (8 μm porous), with UTP (100 μM) in the lower chamber as a chemoattractant. The cells were preincubated in the presence or absence of PGE₂ (1 μM) for 5 min prior to being placed on the insert. After 18 h, cell migration was determined as described in Section “Materials and Methods.” Similar experiments were carried out with cells pretreated for 20 min with U0126 (10 μM). **(B)** *In vitro* wound-healing assay. Wound-healing experiments were carried out after inducing a standard wound in an astrocyte monolayer, washing with PBS and analyzing cell replenishment after 24 h. Where indicated the cells were preincubated with PGE₂ (1 μM) for 5 min prior to UTP (100 μM) stimulation. **(C)** Representative images of cell nuclei revealed with DAPI staining in a wound-healing experiment (Magnification 10X). Scale bar = 200 μm. The results are expressed as the means ± SEM of migrating (%) or invading cells (number of cells) with respect to that obtained in control conditions, in the absence of any effectors. ****p* < 0.0001 according to one way analysis of variance and Dunnett’s post-test.

Considering that co-stimulation of astrocytes with PGE₂ and UTP reproduced the inhibitory effect observed in cells previously exposed to PGE₂, and intracellular calcium mobilization is one of the first steps of the intracellular cascades triggered by GPCRs, the target/s of PGE₂ might be located at the plasma membrane. This raises the question as to whether the activity of PGE₂ is mediated by EP receptors, and what might be the intracellular mechanism and the final target of PGE₂ used to impair the responses to UTP. Moreover, it raises interest in the physiological implications of the cross-talk between PGE₂ and P2Y nucleotide receptors in these glial cells. Focusing on the possible interaction of PGE₂ with EP receptors, all four subtypes of EP receptors (EP1–EP4) have been described in the brain, and they are present in neurons and glial

cells (Sang et al., 2005; Di Cesare et al., 2006; Kunori et al., 2011). The presence of functional EP1 receptors in cerebellar astrocytes was ruled out as PGE₂ and its analogs did not induce calcium responses. These findings contrast to those of astrocytes isolated from other brain sites, such as the hippocampus and cortex (Bezzi et al., 1998; Di Cesare et al., 2006). Rat cortical astrocytes were sensitive to PGE₂ (1 μM) challenges, EP1, EP2/EP4, and EP3 receptors evoking calcium responses heterogeneously in the astrocyte population. Moreover, in cortical astrocytes, calcium responses mediated by EP2/EP4 receptors were reproduced by isoproterenol, a β-agonist, and forskolin, a direct adenylate cyclase activator (Di Cesare et al., 2006). In cerebellar astrocytes neither isoproterenol nor forskolin triggered calcium responses




(Jimenez et al., 1999), whereas extracellular signals coupled to adenylate cyclase stimulation strongly potentiated metabotropic ATP calcium responses. This potentiation was parallel to but independent of cAMP accumulation, suggesting the involvement of $\beta\gamma$ subunits released after G_s stimulation. The data reported here indicated that PGE₂ was unable to potentiate UTP calcium responses, suggesting that EP2/EP4 receptors were neither present nor involved in the inhibitory effect of PGE₂, although their presence cannot be ruled out. PGE₂ has been shown to evoke calcium responses and potentiated glutamate-induced calcium signaling in astrocytes from the OVLT (organum vasculosum laminae terminalis) and MnPO (median preoptic nucleus), contributing to the manifestation of fever (Simm et al., 2016).

The effects of PGE₂ in cerebellar astrocytes could be mediated by EP3 receptors, as they were detected by immunoblotting and sulprostone reproduced all the modulatory roles of the prostaglandin (Figure 9). Sulprostone was even more potent than PGE₂ in reducing UTP-induced ERK activation, and this EP3 agonist slightly increased ERK phosphorylation in unstimulated cells and prevented UTP-induced Akt phosphorylation. The expression of EP3 receptors increased following exposure to LPS, consistent with the increase in these receptors in astrocytes and microglia after ischemic stroke (Han et al., 2016). Nevertheless, the actions of the two agonists assayed, the physiological and the synthetic PGE₂ analog, were not reversed by the EP3 receptor antagonist, L798106, which depressed UTP calcium responses. However, L79829 might also interact with P2 nucleotide receptors, acting as a non-competitive antagonist. The interaction of PGE₂ with EP3 receptors could induce Gi/o protein

recruitment, a mechanism possibly responsible for the inhibition of UTP calcium responses. In cerebellar astrocytes, metabotropic calcium responses and ERK activation induced by the nucleotide were sensitive to PTX (Carrasquero, 2008), and PGE₂ abolished the PTX-sensitive component of UTP calcium responses. Thus, an effect on G protein recruitment could also account for the reduction of ERK activation by PGE₂ and sulprostone described previously. To identify the target and the pathway involved in the modulation of UTP responses by PGE₂, we extended the signaling studies to the PI3K/Akt axis that plays a key role in the nervous system, in development, neuroprotection, proliferation and cancer (Ortega et al., 2008, 2009; Fransson et al., 2013). As expected, UTP induced Akt phosphorylation, agreeing with data reported in rat cortical astrocytes (Jacques-Silva et al., 2004). Moreover, PGE₂ decreased both the basal phosphorylation of Akt and that Akt induced by the nucleotide.

The PI3K axis can be activated by Gi/o-proteins and/or the transactivation of tyrosine kinase receptors that are also present in cortical and cerebellar astrocytes, including EGF and NGF receptors (Lenz et al., 2001; Jimenez et al., 2002; Delicado et al., 2005). The treatment of astrocytes with AG1478 reduces the basal phosphorylation of ERKs and Akt, revealing that EGFR transactivation lies upstream of these kinases. This may not be surprising as the cells are cultured with FCS, although this did not affect the ERK phosphorylation induced by UTP, which was even higher than that obtained in control conditions, nor Akt phosphorylation. AG1478 strongly impeded the modulatory action of PGE₂, suggesting that transactivation of EGFR is one step of the intracellular mechanism triggered by the PGE₂, opening new roles for the EGFR in rat





cerebellar astrocytes. It was clearly demonstrated that EGFR participates in the inhibition of UTP responses displayed by PGE₂ when high nucleotide concentrations accompany PGE₂ in the extracellular milieu. However, when the nucleotide levels diminish EGFR can contribute to the maintenance of the actions of nucleotides, as EGF potentiated previously ineffective UTP/ATP concentrations.

Subsequent studies with LY294002 revealed that PI3K inhibition has similar effects to EGFR inhibition, which would make it interesting to explore the targets of Akt. More than 50 substrates have been identified for this protein, the phosphorylation of which might positively or negatively modulate their functions, alter their subcellular localization, or modify their stability (Liao and Hung, 2010). One of the most relevant substrates is glycogen synthase kinase 3 (GSK3), which regulates cell metabolism and survival in the nervous system (Bhat et al., 2004). Unpublished results (not shown) indicate that GSK3 is also phosphorylated in astrocytes after

UTP stimulation to a similar extent as Akt, although PGE₂ only reduced UTP-induced phosphorylation by 20%. GSK3 is a well-known negative regulator of the enzyme responsible for the glycogen synthesis, glycogen synthase. Glycogen is mainly synthesized and accumulated in astrocytes, and it is mobilized and transformed into lactate to be supplied for neurons in situations of hypoxia or upon demand (Suzuki et al., 2011).

PI3K might also interact with some PKC isoforms regulating their activation. Some PKC isoforms present in cerebellar astrocytes can interact with this kinase, such as PKC-α, -δ, and -ζ identified in cortical astrocytes (Chen and Chen, 1996). In neuroblastoma cells, the atypical PKC-ζ dampened Akt phosphorylation, thereby providing a negative feedback loop to regulate P2X7 expression (Gomez-Villafuertes et al., 2015). In cerebellar astrocytes, it could be responsible for decreasing GSK3 phosphorylation, although we did not find evidence of an involvement of PKC-ζ in this phenomenon. The involvement of other PKC isoforms cannot be ruled out and nPKC could



be responsible for the phosphorylation of P2Y₂/P2Y₄ receptors, which could be internalized to dampen the calcium responses. Moreover, DAG production/nPKC activation may be required for nucleotides to drive ERK activity in these glial cells, particularly as UTP-P2Y receptors were sensitive to feedback inhibition by

PKC (Jimenez et al., 2000; Flores et al., 2005). In fact, in astrocytes in which nPKC was down-regulated by prolonged exposure to phorbol dibutyrate (PDBu) the UTP calcium responses were stronger than those obtained in control cells (results not shown). In macrophages and fibroblasts, the effect of PGE₂ was dependent

on PKC and PKD activation, although it was also independent of EP receptors (Traves et al., 2013; Pimentel-Santillana et al., 2014).

Physiological Implications

This study aimed to explore the cross-talk between PGE₂ and UTP-sensitive P2Y receptors in cerebellar astrocytes. We found that PGE₂ negatively modulated UTP responses, as reported previously in macrophages and fibroblasts. However, there were two differences inasmuch as the effect of PGE₂ appeared to be dependent on EP3 receptors and also, it was observed in LPS treated cells. In macrophages the interaction took place in thioglycollate-elicited and alternative macrophages (M2), but not in macrophages activated with the endotoxin (M1). While the metabolic changes that occur during macrophage activation and the transition from M1 to M2 phenotype have been largely explored (Rodríguez-Prados et al., 2010; Traves et al., 2012), this is not the case for astrocytes activated with LPS. Nevertheless, macrophages and astrocytes share some metabolic features and they are constitutively glycolytic (Bolanos, 2016). Hence, it will be very interesting to investigate the metabolic implications of the cross-talk reported in cerebellar astrocytes, both in control conditions and in LPS-treated astrocytes, and the intracellular targets of the endotoxin. The negative effects of PGE₂ on UTP signaling could contribute to limit excessive astrogliosis, which could represent part of the adaptive mechanism to neuroinflammation. Several studies have indicated that both P2Y and P2X receptors are upregulated in the astrogliosis process involving ERK and Akt activation (Franke et al., 2001; Neary et al., 2005; Franke and Illes, 2014). We are developing studies to determine whether P2Y₂/P2Y₄ receptors are upregulated after

prolonged treatment with the endotoxin and whether they can be down-regulated by PGE₂.

AUTHOR CONTRIBUTIONS

ED, LB, and RP-S designed experiments; LP-H, JG-R, MQ, and SG-R performed experiments; ED, RP-S, and MM-P wrote the manuscript; LP-H, JG-R, and MQ made illustrations and generated figures; MM-P and ED directed the project.

FUNDING

This work was funded by the Spanish Ministerio de Economía y Competitividad (MINECO, BFU 2014-53654-P and SAF2014-5249R) and the “Red de Excelencia Consolider-Ingenio Spanish Ion Channel Initiative” (BFU2015-70067REDC); by the Comunidad de Madrid (BRADE-CM S2013/ICE-2958), and by a Fundación Ramón Areces Grants (PR2018/16-02 and OTR02670). LP-H is a recipient of a grant from the European Social Fund through the Youth Employment and the Youth Employment Initiative, JG-R is the recipient of a FPI fellowship and MQ is the recipient of a FPU fellowship.

ACKNOWLEDGMENT

The authors are grateful to Dr. Mark Sefton for his revision of the manuscript.

REFERENCES

- Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B. L., et al. (1998). Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. *Nature* 391, 281–285. doi: 10.1038/34651
- Bhat, R. V., Budd Haerberlein, S. L., and Avila, J. (2004). Glycogen synthase kinase 3: a drug target for CNS therapies. *J. Neurochem.* 89, 1313–1317. doi: 10.1111/j.1471-4159.2004.02422.x
- Bolanos, J. P. (2016). Bioenergetics and redox adaptations of astrocytes to neuronal activity. *J. Neurochem.* 139(Suppl. 2), 115–125. doi: 10.1111/jnc.13486
- Brambilla, R., Neary, J. T., Cattabeni, F., Cottini, L., D'Ippolito, G., Schiller, P. C., et al. (2002). Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is dependent on ERK1/2 but independent of calcium signalling. *J. Neurochem.* 83, 1285–1296. doi: 10.1046/j.1471-4159.2002.01239.x
- Burnstock, G. (2006). Purinergic signalling. *Br. J. Pharmacol.* 147(Suppl. 1), S172–S181. doi: 10.1038/sj.bjpp.0706429
- Carrasquero, L. (2008). *Cascadas de Señalización Activadas por Nucleótidos en Astrocitos de Cerebelo de Rata: Receptores P2X y P2Y Implicados*. Ph.D. Tesis, Universidad Complutense de Madrid, Madrid.
- Carrasquero, L. M., Delicado, E. G., Bustillo, D., Gutierrez-Martin, Y., Artalejo, A. R., and Miras-Portugal, M. T. (2009). P2X7 and P2Y13 purinergic receptors mediate intracellular calcium responses to BzATP in rat cerebellar astrocytes. *J. Neurochem.* 110, 879–889. doi: 10.1111/j.1471-4159.2009.06179.x
- Carrasquero, L. M., Delicado, E. G., Jimenez, A. I., Perez-Sen, R., and Miras-Portugal, M. T. (2005). Cerebellar astrocytes co-express several ADP receptors. Presence of functional P2Y(13)-like receptors. *Purinergic Signal.* 1, 153–159. doi: 10.1007/s11302-005-6211-3
- Chen, B. C., and Lin, W. W. (2000). Pyrimidinoceptor potentiation of macrophage PGE(2) release involved in the induction of nitric oxide synthase. *Br. J. Pharmacol.* 130, 777–786. doi: 10.1038/sj.bjpp.0703375
- Chen, C. C., and Chen, W. C. (1996). ATP-evoked inositol phosphates formation through activation of P2U purinergic receptors in cultured astrocytes: regulation by PKC subtypes alpha, delta, and theta. *Glia* 17, 63–71. doi: 10.1002/(SICI)1098-1136(199605)17:1<63::AID-GLIA6>3.0.CO;2-8
- Colombo, E., and Farina, C. (2016). Astrocytes: key regulators of neuroinflammation. *Trends Immunol.* 37, 608–620. doi: 10.1016/j.it.2016.06.006
- Communi, D., Motte, S., Boeynaems, J. M., and Piroton, S. (1996). Pharmacological characterization of the human P2Y4 receptor. *Eur. J. Pharmacol.* 317, 383–389. doi: 10.1016/S0014-2999(96)00740-6
- Costanzi, S., Mamedova, L., Gao, Z. G., and Jacobson, K. A. (2004). Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. *J. Med. Chem.* 47, 5393–5404. doi: 10.1021/jm049914c
- Dannhardt, G., and Kiefer, W. (2001). Cyclooxygenase inhibitors—current status and future prospects. *Eur. J. Med. Chem.* 36, 109–126. doi: 10.1016/S0223-5234(01)01197-7
- Delicado, E. G., Jimenez, A. I., Carrasquero, L. M., Castro, E., and Miras-Portugal, M. T. (2005). Cross-talk among epidermal growth factor, Ap(5)A, and nucleotide receptors causing enhanced ATP Ca(2+) signaling involves extracellular kinase activation in cerebellar astrocytes. *J. Neurosci. Res.* 81, 789–796. doi: 10.1002/jnr.20609
- Di Cesare, A., Del Piccolo, P., Zacchetti, D., and Grohovaz, F. (2006). EP2 receptor stimulation promotes calcium responses in astrocytes via activation of the adenylyl cyclase pathway. *Cell. Mol. Life Sci.* 63, 2546–2553. doi: 10.1007/s00018-006-6262-9
- Domercq, M., Brambilla, L., Pilati, E., Marchaland, J., Volterra, A., and Bezzi, P. (2006). P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. *J. Biol. Chem.* 281, 30684–30696. doi: 10.1074/jbc.M606429200

- Dwivedi, A. K., Gurjar, V., Kumar, S., and Singh, N. (2015). Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs). *Drug Discov. Today* 20, 863–873. doi: 10.1016/j.drudis.2015.03.004
- Ellis, E. F., Wei, E. P., and Kontos, H. A. (1979). Vasodilation of cat cerebral arterioles by prostaglandins D₂, E₂, G₂, and I₂. *Am. J. Physiol.* 237, H381–H385.
- Erb, L., and Weisman, G. A. (2012). Coupling of P2Y receptors to G proteins and other signaling pathways. *Wiley Interdiscip. Rev. Membr. Transp. Signal.* 1, 789–803. doi: 10.1002/wmts.62
- Flores, R. V., Hernandez-Perez, M. G., Aquino, E., Garrad, R. C., Weisman, G. A., and Gonzalez, F. A. (2005). Agonist-induced phosphorylation and desensitization of the P2Y₂ nucleotide receptor. *Mol. Cell. Biochem.* 280, 35–45. doi: 10.1007/s11010-005-8050-5
- Font-Nieves, M., Sans-Fons, M. G., Gorina, R., Bonfill-Teixidor, E., Salas-Pedro, A., Marquez-Kisinousky, L., et al. (2012). Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E₂ production in astrocytes. *J. Biol. Chem.* 287, 6454–6468. doi: 10.1074/jbc.M111.327874
- Franke, H., and Illes, P. (2014). Nucleotide signaling in astroglial cells. *Neurosci. Lett.* 565, 14–22. doi: 10.1016/j.neulet.2013.09.056
- Franke, H., Krugel, U., Schmidt, R., Grosche, J., Reichenbach, A., and Illes, P. (2001). P₂ receptor-types involved in astroglial cells in vivo. *Br. J. Pharmacol.* 134, 1180–1189. doi: 10.1038/sj.bjp.0704353
- Fransson, S., Abel, F., Kogner, P., Martinsson, T., and Ejeskar, K. (2013). Stage-dependent expression of PI3K/Akt pathway genes in neuroblastoma. *Int. J. Oncol.* 42, 609–616. doi: 10.3892/ijo.2012.1732
- Fujita, T., Tozaki-Saitoh, H., and Inoue, K. (2009). P2Y₁ receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. *Glia* 57, 244–257. doi: 10.1002/glia.20749
- Gomez-Villafuertes, R., Garcia-Huerta, P., Diaz-Hernandez, J. I., and Miras-Portugal, M. T. (2015). PI3K/Akt signaling pathway triggers P2X₇ receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions. *Sci. Rep.* 5:18417. doi: 10.1038/srep18417
- Han, X., Lan, X., Li, Q., Gao, Y., Zhu, W., Cheng, T., et al. (2016). Inhibition of prostaglandin E₂ receptor EP₃ mitigates thrombin-induced brain injury. *J. Cereb. Blood Flow Metab.* 36, 1059–1074. doi: 10.1177/0271678X15606462
- Ho, C., Hicks, J., and Salter, M. W. (1995). A novel P₂-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat. *Br. J. Pharmacol.* 116, 2909–2918. doi: 10.1111/j.1476-5381.1995.tb15944.x
- Howarth, C., Sutherland, B., Choi, H. B., Martin, C., Lind, B. L., Khennouf, L., et al. (2017). A critical role for astrocytes in hypercapnic vasodilation in brain. *J. Neurosci.* 37, 2403–2414. doi: 10.1523/JNEUROSCI.0005-16.2016
- Ito, M., and Matsuoka, I. (2008). Regulation of purinergic signaling by prostaglandin E₂ in murine macrophages. *J. Pharmacol. Sci.* 107, 443–450. doi: 10.1254/jphs.08087FP
- Ito, M., and Matsuoka, I. (2015). Inhibition of P2Y₆ receptor-mediated phospholipase C activation and Ca²⁺ signaling by prostaglandin E₂ in J774 murine macrophages. *Eur. J. Pharmacol.* 749, 124–132. doi: 10.1016/j.ejphar.2014.12.024
- Jacques-Silva, M. C., Rodnight, R., Lenz, G., Liao, Z., Kong, Q., Tran, M., et al. (2004). P2X₇ receptors stimulate AKT phosphorylation in astrocytes. *Br. J. Pharmacol.* 141, 1106–1117. doi: 10.1038/sj.bjp.0705685
- Jimenez, A. I., Castro, E., Communi, D., Boeynaems, J. M., Delicado, E. G., and Miras-Portugal, M. T. (2000). Coexpression of several types of metabotropic nucleotide receptors in single cerebellar astrocytes. *J. Neurochem.* 75, 2071–2079. doi: 10.1046/j.1471-4159.2000.0752071.x
- Jimenez, A. I., Castro, E., Delicado, E. G., and Miras-Portugal, M. T. (2002). Specific diadenosine pentaphosphate receptor coupled to extracellular regulated kinases in cerebellar astrocytes. *J. Neurochem.* 83, 299–308. doi: 10.1046/j.1471-4159.2002.011111.x
- Jimenez, A. I., Castro, E., Mirabet, M., Franco, R., Delicado, E. G., and Miras-Portugal, M. T. (1999). Potentiation of ATP calcium responses by A_{2B} receptor stimulation and other signals coupled to G_s proteins in type-1 cerebellar astrocytes. *Glia* 26, 119–128. doi: 10.1002/(SICI)1098-1136(199904)26:2<119::AID-GLIA3>3.0.CO;2-D
- Kunori, S., Matsumura, S., Okuda-Ashitaka, E., Katano, T., Audoly, L. P., Urade, Y., et al. (2011). A novel role of prostaglandin E₂ in neuropathic pain: blockade of microglial migration in the spinal cord. *Glia* 59, 208–218. doi: 10.1002/glia.21090
- Lazarowski, E. R., Sesma, J. I., Seminario-Vidal, L., and Kreda, S. M. (2011). Molecular mechanisms of purine and pyrimidine nucleotide release. *Adv. Pharmacol.* 61, 221–261. doi: 10.1016/B978-0-12-385526-8.00008-4
- Lenz, G., Goncalves, D., Luo, Z., Avrruch, J., Rodnight, R., and Neary, J. T. (2001). Extracellular ATP stimulates an inhibitory pathway towards growth factor-induced cRaf-1 and MEKK activation in astrocyte cultures. *J. Neurochem.* 77, 1001–1009. doi: 10.1046/j.1471-4159.2001.00299.x
- Liao, Y., and Hung, M. C. (2010). Physiological regulation of Akt activity and stability. *Am. J. Transl. Res.* 2, 19–42.
- Liu, J., Liao, Z., Camden, J., Griffin, K. D., Garrad, R. C., Santiago-Perez, L. I., et al. (2004). Src homology 3 binding sites in the P2Y₂ nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. *J. Biol. Chem.* 279, 8212–8218. doi: 10.1074/jbc.M312230200
- Miras-Portugal, M. T., Gomez-Villafuertes, R., Gualix, J., Diaz-Hernandez, J. I., Artalejo, A. R., Ortega, F., et al. (2016). Nucleotides in neuroregeneration and neuroprotection. *Neuropharmacology* 104, 243–254. doi: 10.1016/j.neuropharm.2015.09.002
- Neary, J. T., Kang, Y., and Shi, Y. F. (2004). Signaling from nucleotide receptors to protein kinase cascades in astrocytes. *Neurochem. Res.* 29, 2037–2042. doi: 10.1007/s11064-004-6876-y
- Neary, J. T., Kang, Y., Tran, M., and Feld, J. (2005). Traumatic injury activates protein kinase B/Akt in cultured astrocytes: role of extracellular ATP and P₂ purinergic receptors. *J. Neurotrauma* 22, 491–500. doi: 10.1089/neu.2005.22.491
- North, R. A. (2016). P2X receptors. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 371: 20150427. doi: 10.1098/rstb.2015.0427
- Oliveira, J. F., Riedel, T., Leichsenring, A., Heine, C., Franke, H., Krugel, U., et al. (2011). Rodent cortical astroglia express in situ functional P2X₇ receptors sensing pathologically high ATP concentrations. *Cereb. Cortex* 21, 806–820. doi: 10.1093/cercor/bhq154
- Ortega, F., Perez-Sen, R., Delicado, E. G., and Miras-Portugal, M. T. (2009). P2X₇ nucleotide receptor is coupled to GSK-3 inhibition and neuroprotection in cerebellar granule neurons. *Neurotox. Res.* 15, 193–204. doi: 10.1007/s12640-009-9020-6
- Ortega, F., Perez-Sen, R., and Miras-Portugal, M. T. (2008). Gi-coupled P2Y-ADP receptor mediates GSK-3 phosphorylation and beta-catenin nuclear translocation in granule neurons. *J. Neurochem.* 104, 62–73. doi: 10.1111/j.1471-4159.2007.05021.x
- Peterson, T. S., Camden, J. M., Wang, Y., Seye, C. I., Wood, W. G., Sun, G. Y., et al. (2010). P2Y₂ nucleotide receptor-mediated responses in brain cells. *Mol. Neurobiol.* 41, 356–366. doi: 10.1007/s12035-010-8115-7
- Pimentel-Santillana, M., Traves, P. G., Perez-Sen, R., Delicado, E. G., Martin-Sanz, P., Miras-Portugal, M. T., et al. (2014). Sustained release of prostaglandin E₂ in fibroblasts expressing ectopically cyclooxygenase 2 impairs P2Y-dependent Ca²⁺(+)-mobilization. *Mediators Inflamm.* 2014:832103. doi: 10.1155/2014/832103
- Rodriguez-Prados, J. C., Traves, P. G., Cuenca, J., Rico, D., Aragonés, J., Martin-Sanz, P., et al. (2010). Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. *J. Immunol.* 185, 605–614. doi: 10.4049/jimmunol.0901698
- Sang, N., Zhang, J., Marcheselli, V., Bazan, N. G., and Chen, C. (2005). Postsynaptically synthesized prostaglandin E₂ (PGE₂) modulates hippocampal synaptic transmission via a presynaptic PGE₂ EP₂ receptor. *J. Neurosci.* 25, 9858–9870. doi: 10.1523/JNEUROSCI.2392-05.2005
- Simm, B., Ott, D., Pollatzek, E., Murgott, J., Gerstberger, R., Rummel, C., et al. (2016). Effects of prostaglandin E₂ on cells cultured from the rat organum vasculosum laminae terminalis and median preoptic nucleus. *Neuroscience* 313, 23–35. doi: 10.1016/j.neuroscience.2015.11.034
- Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000). Cyclooxygenases: structural, cellular, and molecular biology. *Annu. Rev. Biochem.* 69, 145–182. doi: 10.1146/annurev.biochem.69.1.145
- Sofroniew, M. V. (2015). Astrocyte barriers to neurotoxic inflammation. *Nat. Rev. Neurosci.* 16, 249–263. doi: 10.1038/nrn3898
- St-Jacques, B., and Ma, W. (2016). Preferred recycling pathway by internalized PGE₂ EP₄ receptor following agonist stimulation in cultured dorsal root ganglion neurons contributes to enhanced EP₄ receptor sensitivity. *Neuroscience* 326, 56–68. doi: 10.1016/j.neuroscience.2016.04.005

- Sugimoto, Y., and Narumiya, S. (2007). Prostaglandin E receptors. *J. Biol. Chem.* 282, 11613–11617. doi: 10.1074/jbc.R600038200
- Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., et al. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell* 144, 810–823. doi: 10.1016/j.cell.2011.02.018
- Takano, T., Tian, G. F., Peng, W., Lou, N., Libionka, W., Han, X., et al. (2006). Astrocyte-mediated control of cerebral blood flow. *Nat. Neurosci.* 9, 260–267. doi: 10.1038/nn1623
- Traves, P. G., de Atauri, P., Marin, S., Pimentel-Santillana, M., Rodriguez-Prados, J. C., Marin de Mas, I., et al. (2012). Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. *J. Immunol.* 188, 1402–1410. doi: 10.4049/jimmunol.1101781
- Traves, P. G., Pimentel-Santillana, M., Carrasquero, L. M., Perez-Sen, R., Delicado, E. G., Luque, A., et al. (2013). Selective impairment of P2Y signaling by prostaglandin E₂ in macrophages: implications for Ca²⁺-dependent responses. *J. Immunol.* 190, 4226–4235. doi: 10.4049/jimmunol.1203029
- von Kugelgen, I., and Hoffmann, K. (2016). Pharmacology and structure of P2Y receptors. *Neuropharmacology* 104, 50–61. doi: 10.1016/j.neuropharm.2015.10.030
- Zonta, M., Sebelin, A., Gobbo, S., Fellin, T., Pozzan, T., and Carmignoto, G. (2003). Glutamate-mediated cytosolic calcium oscillations regulate a pulsatile prostaglandin release from cultured rat astrocytes. *J. Physiol.* 553, 407–414. doi: 10.1113/jphysiol.2003.046706

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Paniagua-Herranz, Gil-Redondo, Queipo, González-Ramos, Boscá, Pérez-Sen, Miras-Portugal and Delicado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.